<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT2017082935979N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2017-11-14</date_registration>
      <primary_sponsor>Vice chancellor for research in Qazvin university of medical sciences</primary_sponsor>
      <public_title>Comparing the analgesic effect of intrathecal Sufentanil with intravenous Acetaminophen in combination with low-dose Ketamine on labor pain</public_title>
      <acronym>NO</acronym>
      <scientific_title>Comparing the analgesic effect of intrathecal Sufentanil with intravenous Acetaminophen in combination with low-dose ketamine onl abor pain</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2017-04-21</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>120</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/27032</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment.</study_design>
      <phase>2-3</phase>
      <hc_freetext>Analgesia in  Labour.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group :1000 mg of intravenous acetaminophen in 100 ml of normal saline will be injected intravenously in 15 minutes with 0.03 mg / kg of ketamine, and the maintenance dose of ketamine is dosed at a rate of 0.3 mg / kg / hour after 30 minutes from the initial dose and after completing the dilatation or in the event of sleepiness and failure to respond to the simple instructions, it's discontinued. Intervention 2: Control group: Spinal anesthesia will be performed in sitting position by needle number 25 and through inter-vertebral spaces of L3-L4 or L4-L5. 5 μg of sufentanil (1 ml) will be used for spinal anesthesia. Immediately after spinal anesthesia, the pregnant woman will be placed in the back and horizontal position, and she is in this situation for 5 minutes.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan></results_IPD_plan>
      <results_IPD_description></results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Mona Koochak Pour</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Kosar Medical Education Center,Taleghani Street,Qazvin</address>
        <city>Qazvin</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip></zip>
        <telephone>+98 28 3323 6375</telephone>
        <email>Mon_470@yahoo.com</email>
        <affiliation>Qazvin University Of Medical Sciense</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Mona Koochak Pour</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Kosar Medical Education Center,Taleghani Street, Qazvin</address>
        <city>Qazvin</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip></zip>
        <telephone>+98 28 3323 6375</telephone>
        <email>mon_470@yahoo.com</email>
        <affiliation>Qazvin University Medical Sceinces</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Inclusion criteria are as follows:&#13;
o	Pregnant women who are candidates for natural delivery and are in the active phase (Cervical dilatation of 5-3 cm);&#13;
o	Pregnant women with no history of physical and psychological illness or biochemical abnormalities (ASA I class);&#13;
o	Pregnant women who have written and complete consent for the study.&#13;
Exclusion criteria are as follows:&#13;
o	Dissatisfaction pregnant women;&#13;
o	Mother's preeclampsia and eclampsia;&#13;
o	Insulin-dependent diabetes;&#13;
o	Mother drug abuse history;&#13;
o	Using any analgesic method before entering the study;&#13;
o	History of liver disease;&#13;
o	History or presence of bleeding disorder and coagulation disorders in the mother;&#13;
o	using anticoagulant drugs;&#13;
o	History of mental illness or using antidepressants or anticonvulsants;&#13;
o	Any contraindication for spinal anesthesia;&#13;
o	History of allergic reactions or intolerant to the drugs studied (Sufentanil, acetaminophen and ketamine);&#13;
o	Any significant or severe systemic disease that limits usual and natural activities (such as kidney disease that require dialysis, class 2 heart failure and ….).</inclusion_criteria>
      <agemin>no limit</agemin>
      <agemax>no limit</agemax>
      <gender>Female</gender>
      <exclusion_criteria></exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>O74</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Maternal complications arising from the administration of a general or local anaesthetic, analgesic or other sedation during labour and delivery</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group :1000 mg of intravenous acetaminophen in 100 ml of normal saline will be injected intravenously in 15 minutes with 0.03 mg / kg of ketamine, and the maintenance dose of ketamine is dosed at a rate of 0.3 mg / kg / hour after 30 minutes from the initial dose and after completing the dilatation or in the event of sleepiness and failure to respond to the simple instructions, it's discontinued.</i_keyword>
      <i_keyword>Control group: Spinal anesthesia will be performed in sitting position by needle number 25 and through inter-vertebral spaces of L3-L4 or L4-L5. 5 μg of sufentanil (1 ml) will be used for spinal anesthesia. Immediately after spinal anesthesia, the pregnant woman will be placed in the back and horizontal position, and she is in this situation for 5 minutes.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Pain. Timepoint: During the intervention. Method of measurement: VAS.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Age. Timepoint: During Of Intervention. Method of measurement: Year.</sec_outcome>
      <sec_outcome>Weight. Timepoint: During Of Intervention. Method of measurement: kilogram.</sec_outcome>
      <sec_outcome>First stage of Labour. Timepoint: During Of Intervention. Method of measurement: Minute.</sec_outcome>
      <sec_outcome>Neonate APGAR. Timepoint: During Of Intervention. Method of measurement: 1to10.</sec_outcome>
      <sec_outcome>Blood Pressure. Timepoint: During Of Intervention. Method of measurement: Mm Hg.</sec_outcome>
      <sec_outcome>Ephedrine Amount. Timepoint: During Of Intervention. Method of measurement: mg.</sec_outcome>
      <sec_outcome>Heart Beat. Timepoint: During Of Intervention. Method of measurement: Beat per minute.</sec_outcome>
      <sec_outcome>Nausea and Vomiting. Timepoint: During Of Intervention. Method of measurement: Yes/NO.</sec_outcome>
      <sec_outcome>Amount of Natural delivery. Timepoint: During Of Intervention. Method of measurement: Number.</sec_outcome>
      <sec_outcome>Petedin Amount. Timepoint: During Of Intervention. Method of measurement: mg.</sec_outcome>
      <sec_outcome>Second Stage Of Labour. Timepoint: During Of Intervention. Method of measurement: Minute.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Vice chancellor for research in Qazvin university of medical sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2017-04-08</approval_date>
        <contact_name>Ethics Committee, Qazvin University Of Medical Sciences</contact_name>
        <contact_address>Bahonar Bulvar,Qazvin Qazvin  Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
